Ipsen (IPN.PA) Financial Analysis & Valuation | Quarter Chart
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastati... more
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the area... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $13.23B | Exchange | PAR |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | FR | CEO | David G. Loew |
| IPO Date | 2005-12-07 | CAGR | 8.04% |
| Employees | 5,535 | Website | www.ipsen.com |
| Div. Yield | 51.34% | Payout Ratio | 26% |
| Buy Back Yield | 42.55% | Total Yield | 93.89% |
IPN.PA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $12.11B | P/E | 23.03 | Forward P/E | 10.24 | PEG | 1.08 |
| P/S | 0.06 | P/B | 0.06 | P/CF | 0.2 | P/FCF | 0.21 |
| Sales | $8.87B | Sales 1Y | 16.07% | Sales 3Y | 47.21% | Sales 5Y | 157.12% |
| EPS | $6.95 | EPS 1Y | -11.49% | EPS 3Y | 170.49% | EPS 5Y | 156.1% |
| Sales QoQ | 18% | EPS QoQ | 268.18% | Sales QoQ Avg | 5.97% | EPS QoQ Avg | 85.61% |
| Gross Margin | 67.52% | Operating Margin | 30.13% | Profit Margin | 12.67% | ROCE | 21.29% |
| ROA | 7% | ROE | 11% | Altman Z Score | 4.63 | Piotroski Score | 6 |
| Current Ratio | 1.97 | Quick Ratio | 1.84 | Cash Ratio | 1.14 | Op. CF Ratio | 0.4 |
| Debt/Equity | 0.2 | Debt/Assets | 0.13 | Lt Debt/Equity | 0.15 | Lt Debt/Cap. | 0.12 |
| Intrst Cov. | 29.52 | Inventory Turnover | 6.02 | Asset Turnover | 0.54 | Receivables Turnover | 3.66 |
| Enterprise Value | $12.11B | P/E Ratio | 23.03 |
| Forward P/E | 10.24 | PEG Ratio | 1.08 |
| P/S Ratio | 0.06 | P/B Ratio | 0.06 |
| P/CF Ratio | 0.2 | P/FCF Ratio | 0.21 |
| EPS | $6.95 | EPS Growth 1Y | -11.49% |
| EPS Growth 3Y | 170.49% | EPS Growth 5Y | 156.1% |
| Revenue Growth 1Y | 16.07% | Gross Margin | 67.52% |
| Operating Margin | 30.13% | Profit Margin | 12.67% |
| ROE | 11% | ROA | 7% |
| ROCE | 21.29% | Current Ratio | 1.97 |
| Quick Ratio | 1.84 | Cash Ratio | 1.14 |
| Debt/Equity | 0.2 | Interest Coverage | 29.52 |
| Altman Z Score | 4.63 | Piotroski Score | 6 |
Ipsen (IPN.PA) valuation & financials
Ipsen (IPN.PA) has a market capitalization of $13.23B and trades at a price-to-earnings ratio of 23.0. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Ipsen's revenue grew +16.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)